| EPB0234 | Sustained viral load suppression among people living with HIV on Dolutegravir-based regimen in Southern Nigeria | E-poster | Antiretroviral therapies and clinical issues in adults |
| OAB0104 | Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0202 | Prior M184V/I and multiple prior virological failures have no impact on the efficacy of switching HIV+ adults to DTG/3TC through 96Wks in SOLAR-3D | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0204 | High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0205 | Lenacapavir oral bridging maintains efficacy with a similar safety profile when SC LEN cannot be administered | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OALBX0102 | Doravirine/Islatravir (100mg/0.75mg) once daily compared to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as Initial HIV-1 treatment: 48 week results from a double-blind phase 3 trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| TUPEB01 | Association of antiretroviral therapies with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB02 | Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing: week 24 results of the randomized D2ARLING study | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB03 | Efficacy and safety of switching older adults (≥60 years) from first-line art to B/F/TAF in Kenya - a randomized clinical trial (the B/F/TAF elderly study) | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB04 | Similar inflammatory markers after switching to cabotegravir + rilpivirine long-acting vs. continuing bictegravir/emtricitabine/tenofovir alafenamide: data from the Phase 3b SOLAR study | Poster exhibition | Antiretroviral therapies and clinical issues in adults |